In 1981 was created Abiomed, which is appeared as Corporate Investor. The fund was located in North America if to be more exact in United States. The main office of represented Corporate Investor is situated in the Danvers.
We can highlight the next thriving fund investment areas, such as Emergency Medicine, Personal Health. Among the most popular portfolio startups of the fund, we may highlight Reprieve Cardiovascular, Protembis, Magenta Medical. The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
Speaking about the real fund results, this Corporate Investor is 80 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Abiomed performs on 9 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2019. The important activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Abiomed, startups are often financed by Genesis Capital, Exigent Capital, T. Rowe Price. The meaningful sponsors for the fund in investment in the same round are Pitango Venture Capital, JAFCO Japan, Genesis Capital. In the next rounds fund is usually obtained by Pitango Venture Capital, New Enterprise Associates, JVC Investment Partners.
Related Funds
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Protembis | $10M | 13 Sep 2018 | North Rhine-Westphalia | ||
Magenta Medical | $15M | 28 Sep 2017 | North District |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Protembis | $10M | 13 Sep 2018 | North Rhine-Westphalia | ||
Magenta Medical | $15M | 28 Sep 2017 | North District |
